WO2015180678A1 - 环肽类化合物的晶体及其制备方法和用途 - Google Patents

环肽类化合物的晶体及其制备方法和用途 Download PDF

Info

Publication number
WO2015180678A1
WO2015180678A1 PCT/CN2015/080208 CN2015080208W WO2015180678A1 WO 2015180678 A1 WO2015180678 A1 WO 2015180678A1 CN 2015080208 W CN2015080208 W CN 2015080208W WO 2015180678 A1 WO2015180678 A1 WO 2015180678A1
Authority
WO
WIPO (PCT)
Prior art keywords
crystal
cyclic peptide
peptide compound
formula
compound
Prior art date
Application number
PCT/CN2015/080208
Other languages
English (en)
French (fr)
Inventor
刘石东
王修胜
胡集铖
季晓铭
Original Assignee
上海天伟生物制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 上海天伟生物制药有限公司 filed Critical 上海天伟生物制药有限公司
Priority to US15/314,797 priority Critical patent/US10138274B2/en
Priority to JP2016546138A priority patent/JP6491217B2/ja
Priority to EP15800606.4A priority patent/EP3150624A4/en
Publication of WO2015180678A1 publication Critical patent/WO2015180678A1/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/30—Extraction; Separation; Purification by precipitation
    • C07K1/306—Extraction; Separation; Purification by precipitation by crystallization

Definitions

  • This invention relates to novel crystalline forms of compounds, and more particularly to novel crystalline forms of cyclic peptide compounds, and methods of making and using same.
  • Micafungin is a new type of echinocandin antifungal drug that destroys the structure of fungal cells and dissolves them by inhibiting the ⁇ -1,3-D-glucan synthase, a component of the fungal cell wall. Micafungin is widely used to treat various infections, especially those caused by Aspergillus, Candida, Cryptococcus, Mucor, Actinomycetes, Histoplasma, Dermatophytes and Fusarium.
  • Micafungin Sodium (also known as FK463) is the active pharmaceutical ingredient of the drug Mycamine.
  • the chemical structure of micafungin sodium salt is shown in formula I:
  • the compound of the formula I is a polypeptide compound with poor stability, and the degradation product formation may affect its quality and efficacy during transportation or long-term storage. Further, the compound of the formula I is difficult to be crystallized, and is usually in an amorphous state.
  • the compounds of formula I obtained in the above prior art are all amorphous.
  • the molecules of the solid matter in the amorphous state have higher energy than the molecules of the crystalline solid matter, which is due to the ordered and periodic arrangement of the molecules, which reduces the energy of the interaction between the molecules.
  • high-energy substances have poor stability and low-energy substances have good stability.
  • the amorphous state of the compound is less stable than its crystal.
  • WO 03/018615 of Fujisawa Pharmaceutical Co., Ltd. discloses a novel crystal form of the compound of the formula I and a preparation method thereof.
  • WO03/018615 is prepared by dissolving an amorphous compound of formula I in an aqueous single alcohol solution or aqueous acetone solution, and adding a solvent such as ethyl acetate, dichloromethane, acetone and acetonitrile to obtain a needle-like crystal of the compound B82 of the formula I.
  • the crystal was crystallized in an organic solvent, and the morphology under the microscope was needle-like crystals.
  • X-ray powder diffraction had peaks at 2 ⁇ angles of 4.6°, 5.5°, 9.0°, 9.8°, and 16.9°.
  • the inventors carried out the preparation of the B82-type needle crystal according to the method of Example 1 of the patent WO03/018615, and observed the crystal obtained by an optical microscope, and the size was about 1 ⁇ m, which was a fine needle crystal.
  • the inventors found in the process of subsequent filtration, drying and the like of the crystal that since the B82 type crystal is substantially in the form of a fine needle, the crystal of the compound of the formula I is difficult to filter and the operation time is long; before the crystal is dried, the compound of the formula I
  • the solvent content Dry/Wet is about 0.25, and the crystals enclose a large amount of organic solvent. In the drying process, it is necessary to increase the drying temperature or prolong the drying time so that the solvent content meets the requirements of the drug substance. However, the use of the above drying process increases the degradation products of the compound of formula I, which seriously affects the quality and stability of the drug substance.
  • micafungin sodium solid stability is poor, can only be stored at low temperature or a large number of excipients freeze-dried to ensure its stability, which greatly restricts the development of micafungin sodium drug use. If a stable micafungin sodium solid can be found, it can be prepared into a variety of different dosage forms, such as lyophilized powder injections, tablets, capsules, ointments, etc., to facilitate the use of different patients.
  • Another object of the invention is to provide a process for the preparation of the three new crystals.
  • Yet another object of the invention is to provide the use of the three new crystals.
  • the present invention provides three new crystals of the compound of formula I.
  • XRPD X-ray powder diffraction
  • the crystal A has an X-ray powder diffraction (XRPD) pattern having peaks at the following 2 ⁇ angles: 7.5 ⁇ 0.2°, 11.0 ⁇ 0.2°, and 12.4 ⁇ 0.2°.
  • XRPD X-ray powder diffraction
  • the crystal A has an X-ray powder diffraction (XRPD) pattern having a peak at the following 2 ⁇ angle: 13.4 ⁇ 0.2°, 20.2 ⁇ 0.2°.
  • XRPD X-ray powder diffraction
  • the crystal A of the cyclic peptide compound has an X-ray powder diffraction (XRPD) pattern as shown in FIG.
  • XRPD X-ray powder diffraction
  • the crystal B has an X-ray powder diffraction (XRPD) pattern having peaks at the following 2 ⁇ angles: 7.5 ⁇ 0.2°, 8.8 ⁇ 0.2°, 16.6 ⁇ 0.2°, 13.7 ⁇ 0.2 °, 22.5 ⁇ 0.2 °.
  • XRPD X-ray powder diffraction
  • the X-ray powder diffraction (XRPD) pattern of the crystal B has peaks at the following 2 ⁇ angles: 12.6 ⁇ 0.2°, 14.9 ⁇ 0.2°, 15.6 ⁇ 0.2°, 25.1 ⁇ 0.2°.
  • the X-ray powder diffraction (XRPD) pattern of the crystal B has a peak at the following 2 ⁇ angle: 4.4 ⁇ 0.1 °, 5.2 ⁇ 0.1 °, 8.5 ⁇ 0.1 °, 9.6 ⁇ 0.1 °.
  • the X-ray powder diffraction (XRPD) pattern of the crystal B has a peak at the following 2 ⁇ angle: 7.5 ⁇ 0.1 °, 8.8 ⁇ 0.1 °, 16.6 ⁇ 0.1 °, 13.7 ⁇ 0.1 °, 22.5 ⁇ 0.1 °.
  • the X-ray powder diffraction (XRPD) pattern of the crystal B has a peak at the following 2 ⁇ angle: 12.6 ⁇ 0.1°, 14.9 ⁇ 0.1°, 15.6 ⁇ 0.1°, 25.1 ⁇ 0.1°.
  • the crystal B of the cyclic peptide compound has an X-ray powder diffraction (XRPD) pattern as shown in FIG.
  • the crystal B of the cyclic peptide compound has an X-ray powder diffraction (XRPD) pattern as shown in FIG.
  • the crystal B of the cyclic peptide compound has an infrared spectrum as shown in FIG.
  • XRPD X-ray powder shot
  • the crystal C of the cyclic peptide compound has an X-ray powder diffraction (XRPD) pattern as shown in FIG.
  • the B82 type needle crystal disclosed in WO03/018615 has a fine needle-like morphology, is difficult to filter, is difficult to dry, and has poor stability.
  • the solvent system of the crystal of the compound was studied and found to be purely using a two-phase system such as methanol/water, ethanol/water, n-propanol/water, isopropanol/water, isobutanol/water, n-butanol /water, acetonitrile / water, acetone / water, as a crystallization solvent of the compound of formula I, the compound of formula I is precipitated by cooling and / adding an organic solvent, and the precipitated solid is all amorphous by X-ray powder diffraction (XRPD) analysis.
  • XRPD X-ray powder diffraction
  • the inventors did not give up their efforts to continue screening the crystallization solvent system in a three-phase system using different solvent combinations. After a long period of research, the inventors have unexpectedly discovered that a regular columnar crystal can be obtained in a specific three-phase solvent system. Subsequently, we carried out a large number of solvent screening tests to finally obtain three crystals A, crystal B, and crystal C of the compound of formula I with better stability and better morphology, and the preparation process was determined.
  • the crystal A of the present invention is columnar, has large crystal grains, is easy to be filtered, and the solvent in the crystal is easily removed, and more importantly, the stability is remarkably superior to that of the B82 type crystal.
  • Crystals B and C are crystals formed after crystal A is removed from the organic solvent.
  • the residual amount of organic solvent in crystal B and crystal C is determined by gas chromatography according to ICH-Q3C (International Coordinating Committee for Human Drug Registration Technical Requirements, ICH for short). Meet the requirements for residual solvent limits in APIs.
  • the B82 crystal is a crystal obtained by filtration, and the residual solvent is more than 50% without dry removal of the organic solvent.
  • the solvent residue exceeds the limit of the solvent residue in the ICH-Q3C and cannot meet the requirements of the raw material medicine. Therefore, the crystal B and the crystal C in the present invention are far superior to the B82 type crystal in the residual amount of solvent impurities.
  • the inventors further studied the properties of the compound of formula I after various methods and instruments.
  • X-ray powder diffraction also known as “X-ray polycrystalline diffraction (XRD or XRPD)
  • XRD X-ray polycrystalline diffraction
  • An X-ray powder diffractometer is used to generate a series of diffraction patterns when X-rays are transmitted through the crystal, in which different diffraction lines and their intensity are determined by a certain atomic group, thereby determining the crystal structure.
  • Methods for determining X-ray powder diffraction of crystals are known in the art. For example, a copper radiation target is used to acquire a map using an X-ray powder diffractometer of the RIGAKU D/max 2550VB/PC model at a scanning speed of 2° per minute.
  • the crystal A of the compound of the formula I of the present invention has a specific crystal morphology and has a specific characteristic peak in the X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern of the crystal A of the compound of the formula I of the present invention has characteristic peaks at the following 2 ⁇ angles: 3.6 ⁇ 0.2°, 6.4 ⁇ 0.2°, 6.8 ⁇ 0.2°, 9.5 ⁇ 0.2°;
  • the map also has characteristic peaks at the following 2 theta angles: 7.5 ⁇ 0.2°, 11 ⁇ 0.2°, 12.4 ⁇ 0.2°; in another preferred embodiment, the map is also characterized by the following 2 ⁇ angles. Peak: 13.4 ⁇ 0.2 °, 20.2 ⁇ 0.2 °. More preferably, the crystal A of the compound of formula I has an X-ray powder diffraction (XRPD) pattern substantially identical to that of Figure 1.
  • XRPD X-ray powder diffraction
  • the crystal B of the compound of the formula I of the present invention has a specific crystal morphology and has a specific characteristic peak in the X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern of the crystal B of the compound of the formula I of the present invention has characteristic peaks at the following 2 theta angles: 4.4 ⁇ 0.2 °, 5.2 ⁇ 0.2 °, 8.5 ⁇ 0.2 °, 9.6 ⁇ 0.2 °;
  • the map also has characteristic peaks at the following 2 theta angles: 7.5 ⁇ 0.2°, 8.8 ⁇ 0.2°, 16.6 ⁇ 0.2°, 13.7 ⁇ 0.2°, 22.5 ⁇ 0.2°; in another preferred embodiment, The map also has characteristic peaks at the following 2 theta angles: 12.6 ⁇ 0.2°, 14.9 ⁇ 0.2°, 15.6 ⁇ 0.2°, 25.1 ⁇ 0.2°.
  • the X-ray powder diffraction pattern of the crystal B of the compound of the formula I of the present invention has characteristic peaks at the following 2 theta angles: 4.4 ⁇ 0.1 °, 5.2 ⁇ 0.1 °, 8.5 ⁇ 0.1 °, 9.6 ⁇ 0.1 °;
  • the map also has characteristic peaks at the following 2 theta angles: 7.5 ⁇ 0.1 °, 8.8 ⁇ 0.1 °, 16.6 ⁇ 0.1 °, 13.7 ⁇ 0.1 °, 22.5 ⁇ 0.1 °;
  • the map also has characteristic peaks at the following 2 theta angles: 12.6 ⁇ 0.1 °, 14.9 ⁇ 0.1 °, 15.6 ⁇ 0.1 °, 25.1 ⁇ 0.1 °.
  • the crystal B of the compound of formula I has an X-ray powder diffraction (XRPD) pattern substantially identical to that of Figures 3 or 4.
  • the material state of the X-ray powder diffraction method is identified by comparing the relative intensity of the diffraction peaks and the mirror spacing d (or 2 ⁇ ) of the different crystalline drug samples.
  • the deviation of the 2 ⁇ angle of the crystal form is specified: “For different crystalline substances of the same chemical substance, the allowable deviation value of 2 ⁇ should be less than ⁇ 0.2°.
  • the US Pharmacopoeia (USP27, pages 2401-2402) also has relevant regulations. "The diffraction angle of the sample and reference should be consistent within the calibration accuracy of the diffractometer (2 ⁇ value should be reproducible, ⁇ 0.10 degrees)". It can be seen that for two crystals of the same compound, when X-ray powder diffraction pattern The upper characteristic peak deviation is greater than ⁇ 0.2° and is considered to be a different characteristic peak, and the two crystals are different crystal forms.
  • the peak at the 2 ⁇ reflection angle on the X-ray powder diffraction pattern of the crystal B of the compound of the formula I of the present invention is a special feature, which is characteristic of the 2 ⁇ reflection angle on the X-ray powder diffraction pattern of the B82 type crystal disclosed in WO03/018615. There are significant differences in peaks.
  • the crystal B and B82 crystals of the formula I are similar in absorption intensity and 2 ⁇ angle as follows: (1)
  • the crystal B prepared by the present invention has a medium-intensity characteristic absorption peak at 5.1-5.2°, and the B82-type crystal disclosed in WO03/018615
  • the X-ray powder diffraction pattern has an absorption peak only at 5.5°, and the two characteristic peaks differ by 0.3-0.4°, and the error range measured by the Japanese Pharmacopoeia and the US Pharmacopoeia is generally 0.1°.
  • the crystal B prepared by the present invention has medium strength characteristics at 8.4-8.5°.
  • the absorption peak while the X-ray powder diffraction pattern of the B82 type crystal disclosed in WO03/018615 has an absorption peak only at 9.0°, and the two characteristic peaks differ by 0.5-0.6°, and according to the requirements of the Japanese Pharmacopoeia and the United States Pharmacopoeia, and the existing X
  • the error range measured by the ray powder diffractometer is generally within 0.1° and the maximum is not more than 0.2°, so the difference between the two characteristic peaks is not caused by the instrument error, and is indeed a different characteristic peak;
  • the crystal of the present invention B is at 4.4 ° has the strongest characteristic absorption peak, while the strongest characteristic absorption peak of the B82 type crystal is 9.8°.
  • the crystal C of the compound of the formula I of the present invention has a specific crystal morphology and has a specific characteristic peak in the X-ray powder diffraction pattern.
  • the X-ray powder diffraction pattern of the crystal C of the compound of the formula I of the present invention has characteristic peaks at the following 2 theta angles: 4.5 ⁇ 0.2 °, 5.3 ⁇ 0.2 °, 8.6 ⁇ 0.2 °, 9.6 ⁇ 0.2 °.
  • the crystal C of the compound of formula I has an X-ray powder diffraction (XRPD) pattern substantially identical to that of FIG.
  • IR profiling is used to qualitatively identify crystal structures, and methods for their determination are known in the art.
  • the infrared spectrum of the crystal B of the compound of the formula I of the present invention shows characteristic peaks of the following wave numbers: 3341.16 cm -1 , 2954.82 cm -1 , 1256.74 cm -1 , 1505.84 cm -1 , 1436.10 cm -1 , 1255.82 cm -1 , 1178.41 cm -1, 1085.09cm -1, 1046.10cm -1 , 965.79cm -1, 838.03cm -1, 802.51cm -1, 770.45cm -1, 752.44cm -1, 715.64cm -1, 612.14cm -1. It is preferred to have an infrared spectrum substantially identical to that of FIG.
  • the characteristic peak on the infrared spectrum of the crystal B of the compound of the formula I of the present invention is a special feature.
  • the infrared spectrum of the crystal B of the compound of the formula I and the infrared spectrum of the B82 type crystal reported by WO03/018615 are between 1050 cm -1 and 900 cm -1 . There are significant differences in the characteristic peaks of the wavenumbers.
  • the crystal A of the compound of the formula I of the present invention is a columnar crystal under an optical microscope, and the B82 type crystal is a fine needle-like crystal.
  • the moisture content of the composition of the compound of formula I is determined using a method commonly employed in the art, for example using Karl Fischer (KF).
  • HPLC High Performance Liquid Chromatography
  • Diluent phosphate buffer of water
  • Detection wavelength 210 nm
  • Injection volume 10 ⁇ l.
  • the present invention provides a process for the preparation of crystals of the compounds of formula I.
  • a method for preparing a cyclic peptide compound crystal A comprising the steps of:
  • the cyclic peptide compound crystal A is obtained by cooling and/or adding an organic solvent (i).
  • the alcohol mixed solution in the step (a) is selected from the group consisting of methanol/isobutanol, methanol/isopropanol, and methanol/n-propanol.
  • the volume ratio of the two alcohols is 0.01-100, which is excellent. It is 0.05-20, more preferably 0.1-10.
  • the total volume of the alcohol to the volume ratio of water is from 0.1 to 100, preferably from 0.5 to 10, more preferably from 1 to 7.
  • the temperature of dissolution in the step (a) is from 10 to 50 ° C, preferably from 20 to 40 ° C.
  • step (a) comprises from 1 to 500 mg/ml, preferably from 5 to 100 mg/ml, more preferably from 10 to 50 mg/ml, based on the total volume of the solution.
  • organic solvent (i) in the step (b) is selected from the group consisting of n-propanol, isopropanol, isobutanol, methyl acetate, ethyl acetate, n-propyl acetate, and isopropyl acetate.
  • the temperature of the cooling described in the step (b) is -40 to 35 ° C, preferably -20 to 35 ° C, more preferably -10 to 30 ° C, and most preferably -5 to 15 ° C.
  • volume ratio of the organic solvent (i) in the step (b) to the mixed alcohol solution in the step (a) is from 0.1 to 50, preferably from 0.1 to 10, more preferably from 1 to 5.
  • a method for preparing a cyclic peptide compound crystal B comprising the steps of:
  • Crystal A of the cyclic peptide compound was vacuum dried together with an aqueous system to control the moisture content to obtain crystal B of the cyclic peptide compound.
  • the water system is selected from the group consisting of tap water, pure water, ice water mixture or other substances capable of releasing water vapor.
  • the vacuum drying of the crystal A of the cyclic peptide compound together with the aqueous system means placing the crystal A of the compound of the formula I in a vacuum-dried place where the sample is usually placed, and placing it around the crystal A of the compound of the formula I.
  • the moisture content is controlled at 4%-22%.
  • a method for preparing a cyclic peptide compound crystal C comprising the steps of:
  • the crystal B of the cyclic peptide compound was vacuum dried, and the moisture content was controlled to obtain crystal C of the cyclic peptide compound.
  • controlled moisture content is less than 4%.
  • vacuum drying is a conventional method in the art, such as, but not limited to, drying using a vacuum drying oven.
  • crystals of the compounds of formula I provided herein can also be used directly in the preparation of a medicament for the treatment of fungal infections.
  • a pharmaceutical composition comprising a crystal of a compound of formula I, and a pharmaceutically acceptable carrier can be provided.
  • crystal refers to a solid in which a molecule or atomic complex is in a particular arrangement.
  • the compound of formula I can be obtained using methods conventional in the art, such as, but not limited to, the preparation of the compound as reported in patent WO 96/11210; it is also commercially available, such as, but not limited to, such as Fujisawa Corporation of Japan.
  • the term "pharmaceutically acceptable carrier” refers to a carrier for the administration of a therapeutic agent, including various excipients and diluents.
  • the term refers to pharmaceutical carriers which are not themselves essential active ingredients and which are not excessively toxic after administration. Suitable carriers are well known to those of ordinary skill in the art. A thorough discussion of pharmaceutically acceptable excipients can be found in Remington's Pharmaceutical Sciences (Mack Pub. Co., N. J. 1991).
  • Pharmaceutically acceptable carriers in the compositions can include liquids such as water, saline, glycerol and ethanol.
  • auxiliary substances such as disintegrants, wetting agents, emulsifiers, pH buffering substances and the like may also be present in these carriers.
  • a method for preparing a crystalline form of a compound of the formula I is provided, and the method is very suitable for large-scale production with high yield.
  • Figure 1 shows an X-ray powder diffraction (XRPD) pattern of crystal A of the compound of formula I;
  • Figure 2 is a photomicrograph of a crystal of the compound of formula I before filtration.
  • Figure 3 is an X-ray powder diffraction (XRPD) pattern of crystal B of the compound of formula I;
  • Figure 4 is an X-ray powder diffraction (XRPD) pattern of crystal B of the compound of formula I;
  • FIG. 5 shows an infrared (IR) spectrum of crystal B of the compound of formula I.
  • Figure 6 is an X-ray powder diffraction (XRPD) pattern of crystal C of the compound of formula I;
  • Figure 7 shows an amorphous X-ray powder diffraction (XRPD) pattern of a compound of formula I.
  • Figure 8 is a HPLC chromatogram of crystal B of the compound of formula I obtained in Example 11 after 25 days at 25 °C.
  • Fig. 9 is a HPLC chart of the B82 type crystal obtained in Comparative Example 1 at 25 ° C for 30 days.
  • the units in the weight percent by volume in the present invention are well known to those skilled in the art and, for example, refer to the weight of the solute in a 100 ml solution.
  • the GC (gas chromatography) determination method for residual crystal solvent is determined by the second method of Appendix VIIIP of the Chinese Pharmacopoeia 2010 edition.
  • the column used is a capillary column with polyethylene glycol as a fixed solution.
  • the initial temperature is 40 ° C, maintained for 5 min, heated to 60 ° C at 5 ° C / min, and then heated to 240 ° C at 30 ° C / min, maintained for 3 min, the inlet temperature is 200 ° C, the detector temperature is 260 ° C,
  • the headspace bottle has an equilibrium temperature of 120 ° C and an equilibration time of 20 min.
  • Example 1 of the patent WO03/018615 a needle crystal was obtained, which was a B82 type crystal.
  • the total amount of solvent residual of the B82 type crystal was determined by GC (gas chromatography) to be 72.8% by mass.
  • a solid amorphous powder of the compound of formula I is prepared according to the method of U.S. Patent No. 7,199,248, the X-ray powder diffraction pattern of which is shown in Figure 7.
  • the obtained crystals were placed in a vacuum drying oven, and a disk of ice water mixture was placed at the bottom of the drying oven to control the water content of 22%, and dried under vacuum to obtain crystal B.
  • the total amount of residual solvent of the crystal A was determined by GC (gas chromatography) to be 0.6% by mass.
  • the crystal A obtained in Example 2 was placed in a vacuum drying oven, and a tray of tap water was placed in the bottom of the drying oven to control the water content of 12.1%.
  • the crystal B was obtained by vacuum drying, and the XRPD pattern thereof is shown in Fig. 4.
  • the total amount of residual solvent of the crystal A was determined by GC (gas chromatography) to be 0.7% by mass.
  • the crystal A obtained in Example 6 was placed in a vacuum drying oven, and a tray of crushed ice was placed in the bottom of the drying oven to control the water content by 4%, and dried under vacuum to obtain crystal B.
  • the total amount of the residual solvent of the crystal A was determined by GC (gas chromatography) to be 0.8% by mass.
  • the obtained crystal was placed in a vacuum drying oven, and a disk of pure water was placed in the bottom of the drying oven to control the water content of 7.6%, and dried under vacuum to obtain crystal B of the compound of the formula I.
  • the pure water was removed and vacuum drying was continued.
  • the moisture content was found to be 3.7%, the crystal C of the compound of the formula I was obtained.
  • the total amount of the residual solvent of the crystal A was determined by GC (gas chromatography) to be 0.5% by mass.
  • the crystal B obtained in Example 13 was vacuum dried, and when the moisture content was found to be 2.9%, the crystal C was obtained.
  • the total amount of residual solvent of the crystal A was determined by GC (gas chromatography) to be 0.4% by mass.
  • the crystal B obtained in Example 14 was vacuum dried, and when the moisture content was found to be 0.8%, the crystal C was obtained.
  • the total amount of residual solvent of the crystal A was determined by GC (gas chromatography) to be 0.4% by mass.
  • methanol: water 3:2
  • the preparation process is as follows: the stabilizer is dissolved in 200 ml of water, the crystal of the compound of the formula I is added to dissolve it, the pH is adjusted, and it is placed in 100 10 ml-volume vials, and the obtained pharmaceutical composition is lyophilized.
  • the composition of each formulation of the composition before lyophilization is as follows:
  • the crystal A of the compound of the formula I obtained in Example 2 was measured by an X-ray powder diffractometer, and its X-ray powder diffraction pattern had characteristic peaks at the following 2 ⁇ angles: 3.6°, 6.4°, 6.8°, 7.5°, 9.4°, 10.8. °, 12.4 °, 13.6 °, 20.4 °, X-ray powder diffraction pattern shown in Figure 1.
  • the crystal A of the compound of the formula I is a columnar crystal under an optical microscope, and the shape before filtration is as shown in FIG.
  • Example 3-10 The crystal structure and shape of Example 3-10 were the same as those of Example 2. It can be seen that the process of the invention is very reproducible and a stable crystal A of the compound of formula I can be obtained.
  • the crystal B of the compound of the formula I obtained in Example 11 was measured by an X-ray powder diffractometer, and its X-ray powder diffraction pattern had characteristic peaks at the following 2 ⁇ angles: 4.4°, 5.2°, 7.5°, 8.5°, 8.8°, 9.6. °, 12.6 °, 13.7 °, 14.9 °, 15.7 °, 16.7 °, 22.5 °, 25.1 °, X-ray powder diffraction pattern shown in Figure 3.
  • the crystal B of the compound of the formula I obtained in Example 13 was measured by an X-ray powder diffractometer, and its X-ray powder diffraction pattern had characteristic peaks at the following 2 ⁇ angles: 4.4°, 5.1°, 7.4°, 8.4°, 8.7°, 9.5. °, 12.6 °, 13.6 °, 14.8 °, 15.5 °, 16.6 °, 22.4 °, 25.0 °, X-ray powder diffraction pattern shown in Figure 4.
  • the infrared spectrum of the crystal B of the compound of the formula I is shown in Fig. 5, and shows the following wave number characteristic peaks: 3341.16 cm -1 , 2954.82 cm -1 , 2874.54 cm -1 , 2364.47 cm -1 , 2083.34 cm -1 , 1625.74 cm - 1 ,1505.84cm -1 ,1436.10cm -1 ,1389.34cm -1 ,1255.82cm -1 ,1178.41cm -1 ,1114.04cm -1 ,1085.09cm -1 ,1046.10cm -1 ,965.79cm -1 ,838.03cm - 1 , 770.45 cm -1 , 752.44 cm -1 , 802.51 cm -1 , 715.64 cm -1 , 612.14 cm -1 , 583.00 cm -1 , 505.24 cm -1 .
  • Test Examples 12 to 14 were identical to those of Example 11. It can be seen that the process of the invention is very reproducible and a stable crystal B of the compound of formula I can be obtained.
  • the crystal C of the compound of the formula I obtained in Example 15 was measured by an X-ray powder diffractometer, and its X-ray powder diffraction pattern had characteristic peaks at the following 2 ⁇ angles: 4.5°, 5.2°, 8.5°, 9.6°, X-ray powder diffraction. The figure is shown in Figure 6.
  • Test Examples 16-18 were identical to those of Example 15. It can be seen that the process of the invention is very reproducible and a stable crystal C of the compound of formula I can be obtained.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

本发明公开了环肽类化合物的新晶型，其结构如式I所示，并且公开了其制备方法和用途。

Description

环肽类化合物的晶体及其制备方法和用途 技术领域
本发明涉及化合物新晶型，更具体地涉及环肽类化合物的新晶型及其制备方法和用途。
背景技术
米卡芬净(Micafungin)是一种新型棘白菌素类抗真菌药物，通过抑制真菌细胞壁的组成成分β-1,3-D-葡聚糖合成酶，破坏真菌细胞结构，使之溶解。米卡芬净广泛用于治疗各种感染，尤其是曲霉菌、念珠菌、隐球菌、毛霉菌、放线菌、组织胞浆菌、皮肤癣菌和镰刀菌等引起的感染。
米卡芬净钠(Micafungin Sodium，又称FK463)是药品Mycamine(米开民)的活性药物成分。米卡芬净钠盐的化学结构如式Ⅰ所示：
Figure PCTCN2015080208-appb-000001
5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(R)-2-氨甲酰基-1-羟乙基]-11,20,21,25-四羟基-15-[(R)-1-羟乙基]-26-甲基-2,5,8,14,17,23-六氧-18-[4-[5-(4-戊氧基苯基)异恶唑-3-基]苯甲酰氨基]-1,4,7,13,16,22-六氮杂三环[22.3.0.09,13]二十七-6-基]-1,2-二羟乙基]-2-羟苯基硫酸钠。
式I化合物为多肽类化合物，稳定性差，在运输或长期保存时，会有降解产物生成影响其质量和药效。且式I化合物难于被结晶，通常情况下为无定形状态。
美国专利6,107,458和7,199,248以及WO96/11210公开了制备和提纯式I化合物的方法。其中，美国专利7,199,248将米卡芬净DIPEA(二异丙基乙基胺)盐通过过滤和色谱分离提纯后，再使用丙酮和乙酸乙酯沉淀，得到无定型的式I化合物。
Atsushi Ohigashi等人在Journal of Synthesit Organic Chemistry(合成有机化学杂志)2006年第64卷第12期上发表的论文“Process Development of Micafungin,a Novel Lipopeptide Antifungal Agent”中介绍，在式I化合物的 离子交换洗脱溶液中加入丙酮和乙酸乙酯混合液使式I化合物沉淀，能够得到无定型的式I化合物。式I化合物沉淀物干燥前溶剂含量高(Dry/Wet＝0.25)，式I化合物沉淀物中含有约75％的溶剂，需要延长干燥时间才能有效去除溶剂，然而延长干燥时间会使式I化合物降解物增加，纯度降低。
上述现有技术所获得的式I化合物都为无定型的。无定型状态下的固体物质的分子较晶态固体物质的分子有更高的能量，这是由于分子的有序和周期性排列，降低了分子间的相互作用的能量。按照热力学原理，高能量的物质稳定性差，低能量的物质稳定性好。通常情况下，化合物无定型状态稳定性低于其晶体。
此外，藤泽药品工业株式会社的专利申请WO03/018615公开了一种式I化合物的新晶型及其制备方法。WO03/018615使用无定型的式I化合物溶解在含水的单一醇类溶液或含水的丙酮溶液中，加入乙酸乙酯、二氯甲烷、丙酮和乙腈等溶剂，得到式I化合物B82型针状晶体。该晶体在有机溶剂中结晶得到，显微镜下形态为针状晶体，X-射线粉末衍射在2θ角4.6°、5.5°、9.0°、9.8°、16.9°有峰。
藤泽药品工业株式会社，YAMASHITA等人在生物工学杂志2005年第83卷发表的论文“Study of Industrial Manufacturing Methods for Micafungin(FK463)中提到FK463通过溶剂的优化和PH的控制成功得到针状晶体，但没有具体的实施方式和晶体数据。由于该公司在先的专利申请WO03/018615公开了式I化合物的B82型针状晶体，可见YAMASHITA等人获得的也是B82型针状晶体。
本发明人按照专利WO03/018615实施例1的方法进行了B82型针状晶体的制备，使用光学显微镜观察所获得的晶体，尺寸约为1um，为细小针状晶体。本发明人在对晶体进行后续过滤、干燥等工艺步骤操作时发现，由于B82型晶体基本上为细小针状形态，导致式I化合物晶体过滤困难，操作时间长；晶体干燥前，式I化合物的溶剂含量Dry/Wet约为0.25，晶体包裹大量有机溶剂。干燥过程中需要通过提高干燥温度或延长干燥时间才能使溶剂含量符合原料药要求。但采用上述的干燥过程会使式I化合物的降解产物增加，严重影响原料药的质量和稳定性。
目前所公开的米卡芬净钠固体稳定性较差，只能在低温下保存或添加大量赋形剂冻干保证其稳定性，大大制约了米卡芬净钠药品用途的发展。如果能够找到一种稳定的米卡芬净钠固体，就能够将其制备成多种不同剂型，例如冻干粉针剂、片剂、胶囊、软膏剂等，方便不同的患者使用。
因此本领域迫切需要获得一种稳定性更好、更容易过滤、干燥的式I化合物的新晶型，以便能够更好的实现商业化生产。
发明内容
本发明的一个目的在于提供三种式I化合物的新晶体。
本发明的另一个目的是提供所述三种新晶体的制备方法。
本发明的又一个目的是提供所述三种新晶体的用途。
式I化合物晶体
本发明提供了式I化合物的三种新晶体。
晶体A
一种环肽类化合物的晶体A，其结构如式I所示，所述晶体A的X-射线粉末衍射(XRPD)图上在下述2θ角有峰：3.6±0.2°，6.4±0.2°，6.8±0.2°,9.5±0.2°。
在本发明的另一优选例中，所述晶体A的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：7.5±0.2°，11.0±0.2°，12.4±0.2°。
在本发明的另一优选例中，所述晶体A的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：13.4±0.2°，20.2±0.2°。
在本发明的另一优选例中，所述环肽类化合物的晶体A有如图1所示的X-射线粉末衍射(XRPD)图谱。
晶体B
一种环肽类化合物的晶体B，其结构如式I所示，所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角有峰：4.4±0.2°，5.2±0.2°，8.5±0.2°，9.6±0.2°。
在本发明的另一优选例中，所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：7.5±0.2°，8.8±0.2°，16.6±0.2°，13.7±0.2°，22.5±0.2°。
在本发明的另一优选例中，所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：12.6±0.2°，14.9±0.2°，15.6±0.2°，25.1±0.2°。
在本发明的另一优选例中，所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角有峰：4.4±0.1°，5.2±0.1°，8.5±0.1°，9.6±0.1°。
在本发明的另一优选例中，所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：7.5±0.1°，8.8±0.1°，16.6±0.1°，13.7±0.1°，22.5±0.1°。
在本发明的另一优选例中，所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：12.6±0.1°，14.9±0.1°，15.6±0.1°，25.1±0.1°。
在本发明的另一优选例中，所述环肽类化合物的晶体B有如图3所示的X-射线粉末衍射(XRPD)图谱。
在本发明的另一优选例中，所述环肽类化合物的晶体B有如图4所示的X-射线粉末衍射(XRPD)图谱。
在本发明的另一优选例中，所述环肽类化合物的晶体B有如图5所示的红外光谱。
晶体C
一种环肽类化合物的晶体C，其结构如式I所示，所述晶体C的X-射线粉末射(XRPD)图上在下述2θ角有峰：4.5±0.2°，5.3±0.2°，8.6±0.2°，9.6±0.2°。
在本发明的另一优选例中，所述环肽类化合物的晶体C有如图6所示的X-射线粉末衍射(XRPD)图谱。
WO03/018615公开的B82型针状晶体为细小针状形态，过滤困难、难于干燥且稳定性较差。发明人为了能够获得稳定性更好、形态更优的式I化合物的新晶体，对式I化 合物结晶的溶剂体系进行了研究，研究发现：单纯的利用两相体系，例如甲醇/水，乙醇/水，正丙醇/水，异丙醇/水,异丁醇/水,正丁醇/水，乙腈/水，丙酮/水，作为式I化合物的结晶溶剂，通过降温和/添加有机溶剂使得式I化合物析出，析出的固体经X-射线粉末衍射(XRPD)分析全部为无定型态且稳定性很差。在进一步研究过程中，我们在上述两项体系中对水的比例以及结晶pH进行了大量的调整，统计下来有236个不同体系的组合溶剂体系，但最终发现获得全部是无定型态的产物。
发明人没有放弃努力，继续在三相体系中利用不同的溶剂组合筛选结晶溶剂体系。经过很长一段时间的研究，本发明人意外的发现，在特定的三相的溶剂体系中，能得到形态规则的柱状晶体。随后我们进行了大量的溶剂筛选试验，最终得到三种稳定性更好、形态更优的式I化合物的晶体A、晶体B、晶体C，并且确定了制备工艺。与WO03/018615公开的B82型针状晶体相比，本发明的晶体A为柱状，晶体颗粒大，易于过滤且晶体中的溶剂容易去除，更重要的是稳定性明显优于B82型晶体。晶体B和C是晶体A脱去有机溶剂后形成的晶体，气相色谱检测晶体B和晶体C中有机溶剂残留量符合ICH-Q3C(人用药物注册技术要求国际协调会,简称ICH)的标准，符合原料药中关于残留溶剂限度的要求。但是B82型晶体为过滤得到的晶体，未经干去除有机溶剂等工艺步骤，残留溶剂超过50％，远远超过ICH-Q3C中溶剂残留的限度，无法满足原料药的要求。因此本发明中的晶体B和晶体C在溶剂杂质残留量上远远优于B82型晶体。
式I化合物晶体的鉴定和性质
本发明人在获得式I化合物晶体后进一步采用多种方式和仪器对其性质进行了研究。
“X射线粉末衍射”又称“X射线多晶衍射(XRD或XRPD)”是目前用于测定晶体构造(即晶型)的常用试验方法。采用X射线粉末衍射仪，在X射线透过晶体时产生一系列衍射图谱，该图谱中不同的衍射线及其强度有一定结构的原子团所决定，由此确定晶体结构。测定晶体的X射线粉末衍射的方法在本领域是已知的。例如使用RIGAKU D/max 2550VB/PC型号的X射线粉末衍射仪，以2°每分钟的扫描速度，采用铜辐射靶获取图谱。
本发明的式I化合物的晶体A具有特定的晶体形态，在X射线粉末衍射图中有特定的特征峰。具体而言，本发明的式I化合物的晶体A的X射线粉末衍射图上在下述2θ角有特征峰：3.6±0.2°，6.4±0.2°，6.8±0.2°,9.5±0.2°；在一个优选的实施方式中，该图谱还在下述2θ角有特征峰：7.5±0.2°，11±0.2°，12.4±0.2°；在另一个优选的实施方式中，该图谱还在下述2θ角有特征峰：13.4±0.2°，20.2±0.2°。更佳地，所述式I化合物的晶体A具有与图1基本一致的X-射线粉末衍射(XRPD)图。
本发明的式I化合物的晶体B具有特定的晶体形态，在X射线粉末衍射图中有特定的特征峰。具体而言，本发明的式I化合物的晶体B的X射线粉末衍射图上在下述2θ角有特征峰：4.4±0.2°，5.2±0.2°，8.5±0.2°，9.6±0.2°；在一个优选 的实施方式中，该图谱还在下述2θ角有特征峰：7.5±0.2°，8.8±0.2°，16.6±0.2°，13.7±0.2°，22.5±0.2°；在另一个优选的实施方式中，该图谱还在下述2θ角有特征峰：12.6±0.2°，14.9±0.2°，15.6±0.2°，25.1±0.2°。在一个优选的实施方式中，本发明的式I化合物的晶体B的X射线粉末衍射图上在下述2θ角有特征峰：4.4±0.1°，5.2±0.1°，8.5±0.1°，9.6±0.1°；在另一个优选的实施方式中，该图谱还在下述2θ角有特征峰：7.5±0.1°，8.8±0.1°，16.6±0.1°，13.7±0.1°，22.5±0.1°；在另一个优选的实施方式中，该图谱还在下述2θ角有特征峰：12.6±0.1°，14.9±0.1°，15.6±0.1°，25.1±0.1°。更佳地，所述式I化合物的晶体B具有与图3或4基本一致的X-射线粉末衍射(XRPD)图。
X射线粉末衍射法的物质状态鉴别是通过比较不同晶型药物样品的衍射峰相对强度与镜面间距d(或2θ)值。日本药典中对晶型2θ角偏差的规定：“对于同种化学药物的不同晶型物质，其2θ的允许偏差值应小于±0.2°。美国药典(USP27，2401-2402页)中也有相关规定：“样品和参考物的衍射角应当在衍射仪校准精度范围内一致(2θ值应可重现，±0.10度)”。可见对于同种化合物的两个晶体而言，当X射线粉末衍射图上特征峰偏差大于±0.2°则被认为是不同的特征峰，两个晶体即是不同的晶型。
本发明的式I化合物的晶体B的X射线粉末衍射图上2θ反射角处的峰是特别的特征，这与WO03/018615公开的B82型晶体的X射线粉末衍射图上2θ反射角处的特征峰存在明显的差别。式I化合物的晶体B和B82型晶体图谱吸收强度和2θ角比较如下：(1)本发明制备的晶体B在5.1-5.2°存在中等强度的特征吸收峰，而WO03/018615公开的B82型晶体的X射线粉末衍射图仅在5.5°有吸收峰，这两个特征峰相差0.3-0.4°，而根据日本药典和美国药典要求，以及现有X射线粉末衍射仪测定的误差范围一般在0.1°以内，最大也不会超过0.2°，所以这两个特征峰的差别不是仪器误差造成的，确实是不同的特征峰；(2)本发明制备的晶体B在8.4-8.5°存在中等强度的特征吸收峰，而WO03/018615公开的B82型晶体的X射线粉末衍射图仅在9.0°有吸收峰，这两个特征峰相差0.5-0.6°，而根据日本药典和美国药典要求，以及现有X射线粉末衍射仪测定的误差范围一般在0.1°以内，最大也不会超过0.2°，所以这两个特征峰的差别不是仪器误差造成的，确实是不同的特征峰；(3)本发明的晶体B在4.4°有最强特征吸收峰，而B82型晶体的最强特征吸收峰为9.8°。因此，本发明制备的式I化合物的晶体B和B82型晶体的X射线粉末衍射图不相同，是两种不同的晶型。
本发明的式I化合物的晶体C具有特定的晶体形态，在X射线粉末衍射图中有特定的特征峰。具体而言，本发明的式I化合物的晶体C的X射线粉末衍射图上在下述2θ角有特征峰：4.5±0.2°，5.3±0.2°，8.6±0.2°，9.6±0.2°。更佳地，所述式I化合物的晶体C具有与图6基本一致的X-射线粉末衍射(XRPD)图。
采用红外图谱法(IR)来定性鉴定晶体结构，其测定方法在本领域是已知的。例如可采用PE Spectrum One B，以KBr：样品＝200：1压片，并在400-4000cm-1范围扫描。
本发明的式I化合物的晶体B的红外图谱显示以下波数有特征峰：3340.16cm-1，2954.82cm-1，1625.74cm-1，1505.84cm-1，1436.10cm-1，1255.82cm-1，1178.41cm-1，1085.09cm-1，1046.10cm-1，965.79cm-1，838.03cm-1，802.51cm-1，770.45cm-1，752.44cm-1，715.64cm-1，612.14cm-1。优选具有与图5基本一致的红外图谱。
本发明的式I化合物的晶体B的红外图谱上的特征峰是特别的特征，式I化合物的晶体B的红外图谱与WO03/018615报道的B82型晶体的红外图谱在1050cm-1-900cm-1波数的特征峰存在明显的差别。
显微分析技术，通过光学显微镜对晶体外形识别达到晶型分析的目的。本发明的式I化合物的晶体A在光学显微镜下为柱状晶体，而B82型晶体为细小针状晶体。
测定式I化合物的组合物的水分含量，采用本领域通用的检测方法，例如使用Karl Fischer(KF)测定水分含量。
“高效液相色谱法”(HPLC)是用于检测化合物纯度的常用方法，是以液体为流动相，采用高压输液系统，将具有不同极性的单一溶剂或不同比例的混合溶剂、缓冲液等流动相泵入装有固定相的色谱柱，在柱内各成分被分离后，进入检测器进行检测，从而实现对试样的分析。本发明中采用HPLC测定式I化合物纯度以及用于样品的稳定性研究，所述的HPLC检测方法如下：
分析柱：YMC-ODS 250×4.6mm，5μm；
流动相：乙腈∶磷酸盐缓冲液(pH 3.0)＝45:70；
流速：1ml/min；
柱温：35℃；
稀释液：水的磷酸盐缓冲液；
检测波长：210nm；
进样量：10μl。
式I化合物晶体的制备
本发明提供式I所示化合物晶体的制备方法。
发明人在研究过程中不仅对结晶溶剂进行了筛选，还通过改变结晶过程中pH，研究了pH对式I化合物晶体的影响。经过大量实验证明，pH并不是式I化合物晶体获得的决定性因素。当使用两相或三相体系溶剂结晶得到无定形式I化合物时，即使改变pH，获得的仍然是无定型固体。而当使用三相体系溶剂结晶获得晶体A后，在保证式I化合物稳定的前提下，即使改变pH结晶，仍然能够得到晶体A。
发明人确定了下述最终获得式I化合物三种新晶体的制备方法：
环肽类化合物晶体A的制备方法，所述方法包含以下步骤：
(a)将如式I所示化合物溶解在含水的醇类混合溶液中；
(b)通过降温和/或添加有机溶剂(ⅰ)，得到所述环肽类化合物晶体A。
其中，步骤(a)中所述醇类混合溶液选自：甲醇/异丁醇、甲醇/异丙醇、甲醇/正丙醇。
其中，步骤(a)中所述含水的醇类混合溶液中，两种醇体积比为0.01-100，优 选0.05-20，更优选0.1-10。
其中，步骤(a)中所述含水的醇类混合溶液中，醇的总体积与水体积比为0.1-100，优选0.5-10，更优选1-7。
其中，步骤(a)中所述溶解的温度为10至50℃，优选20至40℃。
其中，步骤(a)中以所述溶解液的总体积计，其中含有式I化合物1-500mg/ml，优选5-100mg/ml，更优选10-50mg/ml。
其中，步骤(b)中所述有机溶剂(ⅰ)选自：正丙醇、异丙醇、异丁醇、乙酸甲酯、乙酸乙酯、乙酸正丙酯、乙酸异丙酯。
其中，步骤(b)中所述的降温的温度为-40至35℃，优选-20至35℃，更优选-10至30℃，最优选-5至15℃。
其中，步骤(b)中所述有机溶剂(i)与步骤(a)中含水的醇类混合溶液的体积比为0.1-50，优选0.1-10，更优选1-5。
环肽类化合物晶体B的制备方法，所述方法包含以下步骤：
将环肽类化合物的晶体A与水体系一起进行真空干燥，控制水分含量得到环肽类化合物的晶体B。
其中，所述水体系选自：自来水、纯水、冰水混合物或其他能释放水蒸汽的物质。
其中，所述将环肽类化合物的晶体A与水体系一起进行真空干燥，是指将式I化合物的晶体A放置在真空干燥通常放置样品的地方，并在式I化合物的晶体A周围放置盛着能释放水蒸汽的物质的敞开的容器。
其中，所述水分含量控制在4％-22％。
环肽类化合物晶体C的制备方法，所述方法包含以下步骤：
将环肽类化合物的晶体B真空干燥，控制水分含量得到环肽类化合物的晶体C。
其中，所述控制水分含量小于4％。
其中，所述真空干燥为本领域常规方法，例如但不限于，使用真空干燥箱干燥。
式I化合物晶体的用途及其组合物
本发明提供的式I化合物的晶体也可以直接用于制备治疗真菌感染的药物。可以提供一种含有式I化合物的晶体，和药学上可接受的载体的药物组合物。
相关术语
如本文所用，术语“晶体”是指分子或原子复合物呈特定排列形式的固体。
如本文所用，“式I化合物”，“化合物I”和“如式I所示化合物”可以互换使用，都是指一种结构如式I的无定形物或本发明所述式I化合物晶体A-C以外的其他晶型的物质，都是指具有以下结构式的化合物：
Figure PCTCN2015080208-appb-000002
式I化合物可以使用本领域常规的方法获得，例如但不限于，专利WO96/11210报道的该化合物的制备方法；也可以通过商业渠道获得，例如但不限于，如日本藤泽公司。
如本文所用，术语“药学上可接受的载体”指用于治疗剂给药的载体，包括各种赋形剂和稀释剂。该术语指这样一些药剂载体：它们本身并不是必要的活性成分，且施用后没有过分的毒性。合适的载体是本领域普通技术人员所熟知的。在Remington's Pharmaceutical Sciences(Mack Pub.Co.，N.J.1991)中可找到关于药学上可接受的赋形剂的充分讨论。在组合物中药学上可接受的载体可包括液体，如水、盐水、甘油和乙醇。另外，这些载体中还可能存在辅助性的物质，如崩解剂、润湿剂、乳化剂、pH缓冲物质等。
本发明的主要优点在于：
1.提供三种形态规则，稳定性优越的式I化合物晶型，方便运输和存储，解决了现有技术中亟待解决的技术问题。
2.提供了化合物式I化合物晶型的制备方法，且所述方法非常适合规模化生产，收率高。
附图说明
图1所示为式I化合物晶体A的X射线粉末衍射(XRPD)图谱；其中
峰号 2-θ d(A) I％(相对强度)
1 3.6 24.7974 100.0
2 6.4 13.7127 84.0
3 6.8 12.9885 42.9
4 7.5 11.7774 14.0
5 9.4 9.3605 42.8
6 10.8 8.1551 15.5
7 12.4 7.1206 15.8
8 13.6 6.5156 16.7
9 20.4 4.3580 24.6
图2所示为式I化合物晶体A过滤前显微镜观察照片。
图3所示为式I化合物晶体B的X射线粉末衍射(XRPD)图谱；其中
峰号 2-θ d(A) I％(相对强度)
1 4.4 19.8888 100.0
2 5.2 17.0426 46.0
3 7.5 11.8100 20.3
4 8.5 10.3938 55.2
5 8.8 10.0411 46.5
6 9.6 9.2244 69.7
7 12.6 7.0200 19.3
8 13.7 6.4581 25.4
9 14.9 5.9329 20.4
10 15.7 5.6400 25.4
11 16.7 5.3169 41.9
12 22.5 3.9443 43.0
13 25.1 3.5395 38.0
图4所示为式I化合物晶体B的X射线粉末衍射(XRPD)图谱；其中
峰号 2-θ d(A) I％(相对强度)
1 4.4 20.1588 100.0
2 5.1 17.2445 49.4
3 7.4 11.9038 24.8
4 8.4 10.5159 54.1
5 8.7 10.1314 83.6
6 9.5 9.3212 66.8
7 12.6 7.0423 25.9
8 13.6 6.4868 31.3
9 14.8 5.9638 24.6
10 15.5 5.7043 26.0
11 16.6 5.3426 52.3
12 22.4 3.9724 51.0
13 25.0 3.5535 46.1
图5所示为式I化合物晶体B的红外(IR)图谱。
图6所示为式I化合物晶体C的X射线粉末衍射(XRPD)图谱；其中
峰号 2-θ d(A) I％(相对强度)
1 4.5 19.7047 100.0
2 5.2 16.8487 40.0
3 8.5 10.3453 33.1
4 9.6 9.2051 37.3
图7所示为式I化合物无定型的X射线粉末衍射(XRPD)图谱。
图8所示为实施例11获得的式I化合物晶体B在25℃,30天后的HPLC图谱。
图9所示为对比例1获得的B82型晶体在25℃,30天后的HPLC图谱。
具体实施方式
下面结合具体实施例，进一步阐述本发明。应理解，这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法，通常按照常规条件或按照制造厂商所建议的条件。除非另外说明，否则所有的百分数、比率、比例、或份数按重量计。
本发明中的重量体积百分比中的单位是本领域技术人员所熟知的，例如是指在100毫升的溶液中溶质的重量。
除非另行定义，文中所使用的所有专业与科学用语与本领域熟练人员所熟悉的意义相同。此外，任何与所记载内容相似或均等的方法及材料皆可应用于本发明方法中。文中所述的较佳实施方法与材料仅作示范之用。
以下比较例和实施例中，晶体溶剂残留的GC(气相色谱)测定方法参照中国药典2010年版二部附录ⅧP第二法测定，所用的色谱柱为以聚乙二醇为固定液的毛细管色谱柱，起始温度为40℃，维持5min，以5℃/min升温至60℃，再以30℃/min升温至240℃，维持3min，进样口温度为200℃，检测器温度为260℃，顶空瓶平衡温度为120℃，平衡时间为20min。
比较例1
制备B82型晶体
按照专利WO03/018615实施例1方法制备得到针状晶体，为B82型晶体。
GC(气相色谱)测定B82型晶体溶剂残留总量为72.8％(质量百分比)。
实施例1
制备化合物I
按照美国专利7,199,248中方法制备得到式I化合物的固体无定型粉末，其X射线粉末衍射图谱见附图7。
实施例2
制备式I化合物晶体A
将由实施例1制备得到的无定型的式I化合物1g，25℃下溶解于50ml甲醇/异丁醇水溶液(异丁醇：水：甲醇＝8:2:1)中，缓慢降温至8℃，溶液中有晶体析出，并保持此温度继续搅拌3.5h晶体大量析出，慢慢加入90ml乙酸乙酯，过滤前取样在15×40倍的显微镜下观察晶体照片见附图2。过滤得到晶体A，其XRPD图谱见附图1。GC(气相色谱)测定晶体A溶剂残留总量为30.2％(质量百分比)。
实施例3
制备式I化合物晶体A
将由比较例1制备得到的B82型晶体2.5g，30℃下溶解于50ml甲醇/异丁醇水溶液(异丁醇：水：甲醇＝1:1:1)中，慢慢加入50ml乙酸甲酯，过滤得到晶体A。GC(气相色谱)测定晶体A溶剂残留总量为28.4％(质量百分比)。
实施例4
制备式I化合物晶体A
将由实施例1制备得到的无定型的式I化合物3g，10℃下溶解于600ml甲醇/异丁醇水溶液(异丁醇：水：甲醇＝5:1:2)中，降温至-20℃，溶液中有晶体析出，继续搅拌约12h晶体大量析出，过滤得到晶体A。GC(气相色谱)测定晶体A溶剂残留总量为25.1％(质量百分比)。
实施例5
制备式I化合物晶体A
将由实施例1制备得到的无定型的式I化合物3g，50℃下溶解于120ml甲醇/异丙醇水溶液(异丙醇：水：甲醇＝1:4:1)中，降温至30℃，溶液中有晶体析出，继续搅拌30min晶体大量析出，慢慢加入200ml异丙醇，过滤得到晶体A。GC(气相色谱)测定晶体A溶剂残留总量为27.1％(质量百分比)。
实施例6
制备式I化合物晶体A
将由实施例1制备得到的无定型的式I化合物1g，20℃下溶解于20ml甲醇/异丙醇水溶液(异丙醇：水：甲醇＝10:2:1)中，慢慢加入200ml乙酸正丙酯，过滤得到晶体A。GC(气相色谱)测定晶体A溶剂残留总量为26.9％(质量百分比)。
实施例7
制备式I化合物晶体A
将由实施例1制备得到的无定型的式I化合物1.0g，18℃下溶解于100ml甲醇/异丙醇水溶液(异丙醇：水：甲醇＝1:2:20)中，降温至-5℃，溶液中有晶体析出，继续搅拌4h晶体大量析出，过滤得到晶体A。GC(气相色谱)测定晶体A溶剂残留总量为33.4％(质量百分比)。
实施例8
制备式I化合物晶体A
将由实施例1制备得到的无定型的式I化合物2g，30℃下溶解于20ml甲醇/正丙醇水溶液(正丙醇：水：甲醇＝1:15:10)中，降温至15℃，溶液中有晶体析出，继续搅拌2h晶体大量析出，慢慢加入100ml乙酸异丙酯，过滤得到晶体A。GC(气相色谱)测定晶体A溶剂残留总量为32.0％(质量百分比)。
实施例9
制备式I化合物晶体A
将由实施例1制备得到的无定型的式I化合物4g，25℃下溶解于300ml甲醇/正丙醇水溶液(正丙醇：水：甲醇＝20:2:1)中，慢慢加入30ml异丁醇，过滤得到晶体A。GC(气相色谱)测定晶体A溶剂残留总量为35.1％(质量百分比)。
实施例10
制备式I化合物晶体A
将由实施例1制备得到的无定型的式I化合物2.7g，40℃下溶解于80ml甲醇/正丙醇水溶液(正丙醇：水：甲醇＝10:3:1)中，降温至-10℃，溶液中有晶体析出，继续搅拌1h晶体大量析出，过滤得到晶体A。GC(气相色谱)测定晶体A溶剂残留总量为30.0％(质量百分比)。
实施例11
制备式I化合物晶体B
将由实施例1制备得到的无定型的式I化合物1.5g，20℃下溶解于70ml甲醇/异丁醇水溶液(异丁醇：水：甲醇＝8:2:1)中，缓慢降温至0℃，溶液中有晶体析出，并保持此温度继续搅拌4.5h晶体大量析出，慢慢加入100ml乙酸乙酯，过滤得到晶体A。所得晶体放入真空干燥箱中，在干燥箱内底部放一盘纯水，控制含水量17.9％，真空干燥得到晶体B。其XRPD、IR图谱见附图3和5。GC(气相色谱)测定晶体A溶剂残留总量为0.8％(质量百分比)。
实施例12
制备式I化合物晶体B
将由实施例1制备得到的无定型的式I化合物2.3g，35℃下溶解于100ml乙醇/正丙醇水溶液(正丙醇：水：甲醇＝6:2:1)中，降温至10℃，溶液中有晶体析出，并保持此温度继续搅拌3h晶体大量析出，慢慢加入100ml乙酸乙酯，过滤即可得到式I化合物晶体A。所得晶体放入真空干燥箱中，在干燥箱内底部放一盘冰水混合物，控制含水量22％，真空干燥得到晶体B。GC(气相色谱)测定晶体A溶剂残留总量为0.6％(质量百分比)。
实施例13
制备式I化合物晶体B
将实施例2所得到的晶体A，放入真空干燥箱中，在干燥箱内底部放一盘自来水，控制含水量12.1％，真空干燥得到晶体B，其XRPD图谱见附图4。GC(气相色谱)测定晶体A溶剂残留总量为0.7％(质量百分比)。
实施例14
制备式I化合物晶体B
将实施例6所得到的晶体A，放入真空干燥箱中，在干燥箱内底部放一盘碎冰，控制含水量4％，真空干燥得到晶体B。GC(气相色谱)测定晶体A溶剂残留总量为0.8％(质量百分比)。
实施例15
制备式I化合物晶体C
将由实施例1制备得到的无定型的式I化合物2g，27℃下溶解于100ml甲醇/异丁醇水溶液(异丁醇：水：甲醇＝8:2:1)中，缓慢降温至0℃，溶液中有晶体析出，并保持此温度继续搅拌4h晶体大量析出，慢慢加入150ml乙酸乙酯，过滤得到晶体A。所得晶体放入真空干燥箱中，在干燥箱内底部放一盘自来水，控制含水量17.7％，真空干燥即可得到晶体B。撤去自来水，继续真空干燥，当测得水分含量为2.1％时， 得到式I化合物晶体C。其XRPD图谱见附图6。GC(气相色谱)测定晶体A溶剂残留总量为0.5％(质量百分比)。
实施例16
制备式I化合物晶体C
将由实施例1制备得到的无定型的式I化合物3.3g，20℃下溶解于120ml甲醇/异丙醇水溶液(异丙醇：水：甲醇＝3:1:3)中，降温至5℃，溶液中有晶体析出，并保持此温度继续搅拌1.5h晶体大量析出，慢慢加入200ml乙酸正丙酯，过滤既可得到式I化合物晶体A。所得晶体放入真空干燥箱中，在干燥箱内底部放一盘纯水，控制含水量7.6％，真空干燥即可得到式I化合物晶体B。撤去纯水，继续真空干燥，当测得水分含量为3.7％时，得到式I化合物晶体C。GC(气相色谱)测定晶体A溶剂残留总量为0.5％(质量百分比)。
实施例17
制备式I化合物晶体C
将实施例13所得到的晶体B真空干燥，当测得水分含量为2.9％时，得到晶体C。GC(气相色谱)测定晶体A溶剂残留总量为0.4％(质量百分比)。
实施例18
制备式I化合物晶体C
将实施例14所得到的晶体B真空干燥，当测得水分含量为0.8％时，得到晶体C。GC(气相色谱)测定晶体A溶剂残留总量为0.4％(质量百分比)。
比较例2
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物0.8g，25℃下溶解于5ml甲醇水溶液(甲醇：水＝3:2)，缓慢降温至约0℃，溶液中有固体析出，并保持此温度继续搅拌3h，过滤得到固体无定型粉末。
比较例3
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物2.1g，32℃下溶解于50ml乙醇水溶液(乙醇：水＝5:1)中，降温至10℃，溶液中有固体析出，并保持此温度继续搅拌5h，过滤得到固体无定型粉末。
比较例4
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物3g，20℃下溶解于55ml正丙醇水溶液(正丙醇：水＝1:1)中，降温至0℃，溶液中有固体析出，并保持此温度继续搅拌5h，过滤得到固体无定型粉末。
比较例5
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物2.5g，45℃下溶解于32ml异丙醇水溶液(异丙醇：水＝2:3)中，降温至15℃，溶液中有固体析出，并保持此温度继 续搅拌1h，过滤得到固体无定型粉末。
比较例6
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物1.7g，32℃下溶解于90ml异丁醇水溶液(异丁醇：水＝4:1)中，降温至10℃，溶液中有固体析出，并保持此温度继续搅拌2h，过滤得到固体无定型粉末。
比较例7
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物1g，28℃下溶解于50ml正丁醇水溶液(正丁醇：水＝9:1)中，降温至0℃，慢慢加入50ml乙酸甲酯，过滤得到固体无定型粉末。
比较例8
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物1.2g，17℃下溶解于45ml丙酮水溶液(丙酮：水＝4:1)中，降温至-5℃，溶液中有固体析出，并保持此温度继续搅拌3.5h，过滤得到固体无定型粉末。
比较例9
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物5g，25℃下溶解于150ml乙腈水溶液(乙腈：水＝3:1)中，降温至8℃，溶液中有固体析出，并保持此温度继续搅拌2h，慢慢加入200ml乙酸异丙酯，过滤得到固体无定型粉末。
比较例10
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物1.7g，30℃下溶解于100ml甲醇/乙醇水溶液(甲醇：乙醇：水＝8:2:1)中，降温至11℃，溶液中有固体析出，并保持此温度继续搅拌6h，慢慢加入100ml乙酸乙酯，过滤得到固体无定型粉末。
比较例11
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物1.7g，23℃下溶解于100ml丙醇/丁醇水溶液(丙醇：丁醇：水＝6:5:3)中，降温至-5℃，溶液中有固体析出，并保持此温度继续搅拌7h，过滤得到固体无定型粉末。
比较例12
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物4g，45℃下溶解于28ml甲醇/正丁醇水溶液(甲醇：正丁醇：水＝1:7:2)中，降温至11℃，溶液中有固体析出，并保持此温度继续搅拌6h，过滤得到固体无定型粉末。
比较例13
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物1g，20℃下溶解于70ml乙醇/丁醇水溶液(乙醇:丁醇:水＝2:2:5)中，慢慢加入100ml乙酸乙酯，过滤得到固体无定型粉末。
比较例14
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物3g，50℃下溶解于20ml甲醇/乙腈水溶液(甲醇:乙腈:水＝4:1:2)中，降温至25℃，溶液中有固体析出，并保持此温度继续搅拌2h，慢慢加入70ml乙酸乙酯，过滤得到固体无定型粉末。
比较例15
不同溶剂对式I化合物晶型的影响
将由实施例1制备得到的无定型的式I化合物2g，30℃下溶解于10ml甲醇/丙酮水溶液(甲醇:丙酮:水＝9:2:2)中，降温至5℃，溶液中有固体析出，并保持此温度继续搅拌4h，慢慢加入50ml乙酸乙酯，过滤得到固体无定型粉末。
实施例19
纯度和稳定性测试
在本实施例中，将比较例与实施例所得样品的纯度与稳定性进行比较。方法如下：
分别取实施例2、11、15制备得到的式I化合物晶体A-C，比较例1得到的B82型晶体，及实施例1得到的无定型固体，密闭置于25℃保温放置30天，然后分析样品的杂质含量。本发明中式I化合物晶体A-C与B82型晶体、无定型固体稳定性比较结果见下表：
样品 起始样品纯度 25℃，30天样品纯度
晶体A 99.68％ 99.65％
晶体B 99.55％ 99.50％
晶体C 99.64％ 99.43％
B82型晶体 99.50％ 96.98％
无定型固体 99.38％ 89.27％
由表中数据可以明显看出，式I化合物晶体A-C稳定性明显优于B82型晶体，更优于无定型固体。
实施例20
药物组合物的制备
制备过程为：将稳定剂溶于200ml水中，再加入式I化合物晶体使其溶解，调节pH，装到100个10ml体积的小瓶中，冻干获得的药物组合物。冻干前的组合物各配方的组成如下表：
Figure PCTCN2015080208-appb-000003
Figure PCTCN2015080208-appb-000004
实施例21
药物组合物的制备
取按实施例2的方法获得的式I化合物的晶体A 0.2g，实施例11的方法获得的式I化合物的晶体B 0.2g，实施例14的方法获得的式I化合物的晶体C 0.2g,分别按照US2007249546A1实施例2的方法制备成滴眼液。
式I化合物的晶体A的测定
采用X射线粉末衍射仪测定实施例2中获得的式I化合物的晶体A，其X射线粉末衍射图在下述2θ角有特征峰：3.6°，6.4°，6.8°，7.5°,9.4°，10.8°，12.4°，13.6°，20.4°，X射线粉末衍射图如图1所示。
式I化合物的晶体A在光学显微镜下为柱状晶体，过滤前形状如图2所示。
经检测实施例3-10的晶体结构、形状与实施例2的晶体结构、形状相同。可见，本发明方法的重复性很好，可获得稳定的式I化合物的晶体A。
式I化合物的晶体B的测定
采用X射线粉末衍射仪测定实施例11中获得的式I化合物的晶体B，其X射线粉末衍射图在下述2θ角有特征峰：4.4°，5.2°，7.5°，8.5°，8.8°，9.6°，12.6°，13.7°，14.9°，15.7°，16.7°，22.5°，25.1°，X射线粉末衍射图如图3所示。
采用X射线粉末衍射仪测定实施例13中获得的式I化合物的晶体B，其X射线粉末衍射图在下述2θ角有特征峰：4.4°，5.1°，7.4°，8.4°，8.7°，9.5°，12.6°，13.6°，14.8°，15.5°，16.6°，22.4°，25.0°，X射线粉末衍射图如图4所示。
式I化合物的晶体B的红外图谱如图5所示，显示以下波数有特征峰：3340.16cm-1，2954.82cm-1，2874.54cm-1，2364.47cm-1，2083.34cm-1，1625.74cm-1，1505.84cm-1，1436.10cm-1，1389.34cm-1，1255.82cm-1，1178.41cm-1，1114.04cm-1，1085.09cm-1，1046.10cm-1，965.79cm-1，838.03cm-1，770.45cm-1，752.44cm-1，802.51cm-1，715.64cm-1，612.14cm-1，583.00cm-1，505.24cm-1。
经检测实施例12-14的晶体结构与实施例11的晶体结构相同。可见，本发明方法的重复性很好，可获得稳定的式I化合物的晶体B。
式I化合物的晶体C的测定
采用X射线粉末衍射仪测定实施例15中获得的式I化合物的晶体C，其X射线粉末衍射图在下述2θ角有特征峰：4.5°，5.2°，8.5°，9.6°,X射线粉末衍射图如图6所示。
经检测实施例16-18的晶体结构与实施例15的晶体结构相同。可见，本发明方法的重复性很好，可获得稳定的式I化合物的晶体C。
以上所述仅为本发明的较佳实施例而已，并非用以限定本发明的实质技术内容范围，本发明的实质技术内容是广义地定义于申请的权利要求范围中，任何他人完成的技术实体或方法，若是与申请的权利要求范围所定义的完全相同，也或是一种等效的变更，均将被视为涵盖于该权利要求范围之中。

Claims (26)

  1. 一种环肽类化合物的晶体A，其结构如式I所示，所述晶体A的X-射线粉末衍射(XRPD)图上在下述2θ角有峰：3.6±0.2°，6.4±0.2°，6.8±0.2°,9.5±0.2°；
    Figure PCTCN2015080208-appb-100001
  2. 如权利要求1所述的环肽类化合物的晶体A，其特征在于，所述晶体A的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：7.5±0.2°，11.0±0.2°，12.4±0.2°。
  3. 如权利要求2所述的环肽类化合物的晶体A，其特征在于，所述晶体A的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：13.4±0.2°，20.2±0.2°。
  4. 一种环肽类化合物的晶体B，其结构如式I所示，所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角有峰：4.4±0.2°，5.2±0.2°，8.5±0.2°，9.6 ±0.2°；
    Figure PCTCN2015080208-appb-100002
    。
  5. 如权利要求4所述的环肽类化合物的晶体B，其特征在于,所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：7.5±0.2°，8.8±0.2°，16.6±0.2°，13.7±0.2°，22.5±0.2°。
  6. 如权利要求5所述的环肽类化合物的晶体B，其特征在于,所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：12.6±0.2°，14.9±0.2°，15.6±0.2°，25.1±0.2°。
  7. 一种环肽类化合物的晶体C，其结构如式I所示，所述晶体C的X-射线粉末射(XRPD)图上在下述2θ角有峰：4.5±0.2°，5.3±0.2°，8.6±0.2°,9.6±0.2°；
    Figure PCTCN2015080208-appb-100003
  8. 一种制备如权利要求1-3任一所述环肽类化合物晶体A的方法，其特征在于，所述的方法包含以下步骤：
    (a)将如式I所示化合物溶解在含水的醇类混合溶液中；
    (b)通过降温和/或添加有机溶剂(ⅰ)，得到如权利要求1-3任一所述环肽类化合物的晶体A。
  9. 如权利要求8所述的制备方法，其特征在于，步骤(a)中所述醇类混合溶液选自：甲醇/异丁醇、甲醇/异丙醇、甲醇/正丙醇。
  10. 如权利要求9所述的制备方法，其特征在于，步骤(a)中所述含水的醇类混合溶液中，两种醇体积比为0.01-100，优选0.05-20，更优选0.1-10。
  11. 如权利要求8所述的制备方法，其特征在于，步骤(a)中所述含水的醇类混合溶液中，醇的总体积与水体积比为0.1-100，优选0.5-10，更优选1-7。
  12. 如权利要求8所述的制备方法，其特征在于，步骤(b)中所述有机溶剂(ⅰ)选自：正丙醇、异丙醇、异丁醇、乙酸甲酯、乙酸乙酯、乙酸正丙酯、乙酸异丙酯。
  13. 如权利要求8所述的制备方法，其特征在于，步骤(b)中所述的降温的温度为-40至35℃，优选-20至35℃，更优选-10至30℃，最优选-5至15℃。
  14. 如权利要求8所述的制备方法，其特征在于，步骤(b)中所述有机溶剂(i)与步骤(a)中含水的醇类混合溶液的体积比为0.1-50，优选0.1-10，更优选1-5。
  15. 一种制备如权利要求4-6任一所述环肽类化合物的晶体B的方法，其特征在于，所述的方法包含以下步骤：
    将如权利要求1-3任一所述的环肽类化合物的晶体A与水体系一起进行真空干燥，控制水分含量得到如权利要求4-6任一所述环肽类化合物的晶体B。
  16. 如权利要求15所述的制备方法，其特征在于，所述水体系选自：自来水、纯水、冰水混合物或其他能释放水蒸汽的物质。
  17. 如权利要求15所述的制备方法，其特征在于，控制水分含量4％-22％，得到如权利4-6任一所述环肽类化合物的晶体B。
  18. 一种制备如权利要求7所述环肽类化合物的晶体C的方法，其特征在于，所述的方法包含以下步骤：
    将如权利要求4-6任一所述环肽类化合物的晶体B真空干燥，控制水分含量得到如权利要求7所述环肽类化合物的晶体C。
  19. 如权利要求18所述的制备方法，其特征在于，所述控制水分含量小于4％，得到如权利7所述环肽类化合物的晶体C。
  20. 一种如权利要求1-7任一所述的环肽类化合物晶体的用途，其特征在于，用于制备治疗真菌感染的药物。
  21. 一种药物组合物，其特征在于，所述的药物组合物中含有如权利要求1-7任一所述的环肽类化合物晶体和药学上可接受的载体。
  22. 一种如权利要求21所述的药物组合物的制备方法，其特征在于，所述的方法包含以下步骤：
    将如权利要求1-7任一所述的环肽类化合物晶体和药学上可接受的载体混合，得到如权利要求21所述的药物组合物。
  23. 一种环肽类化合物的组合物，其特征在于，所述的组合物中含有权利要求1-3任一所述的环肽类化合物晶体A、权利要求4-6任一所述的环肽类化合物晶体B、权利要求7所述的环肽类化合物晶体C的一种或多种混合物。
  24. 如权利要求4所述的环肽类化合物的晶体B，其特征在于,所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角有峰：4.4±0.1°，5.2±0.1°，8.5±0.1°，9.6±0.1°。
  25. 如权利要求24所述的环肽类化合物的晶体B，其特征在于,所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：7.5±0.1°，8.8±0.1°，16.6±0.1°，13.7±0.1°，22.5±0.1°。
  26. 如权利要求25所述的环肽类化合物的晶体B，其特征在于,所述晶体B的X-射线粉末衍射(XRPD)图上在下述2θ角还有峰：12.6±0.1°，14.9±0.1°，15.6±0.1°，25.1±0.1°。
PCT/CN2015/080208 2014-05-29 2015-05-29 环肽类化合物的晶体及其制备方法和用途 WO2015180678A1 (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US15/314,797 US10138274B2 (en) 2014-05-29 2015-05-29 Crystal of cyclic peptide compound, preparation method for same and uses thereof
JP2016546138A JP6491217B2 (ja) 2014-05-29 2015-05-29 シクロペプチド系化合物の結晶およびその製造方法と使用
EP15800606.4A EP3150624A4 (en) 2014-05-29 2015-05-29 Crystal of cyclic peptide compound, preparation method for same, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201410234082.6 2014-05-29
CN201410234082 2014-05-29

Publications (1)

Publication Number Publication Date
WO2015180678A1 true WO2015180678A1 (zh) 2015-12-03

Family

ID=53944715

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2015/080208 WO2015180678A1 (zh) 2014-05-29 2015-05-29 环肽类化合物的晶体及其制备方法和用途

Country Status (5)

Country Link
US (1) US10138274B2 (zh)
EP (1) EP3150624A4 (zh)
JP (1) JP6491217B2 (zh)
CN (3) CN108276478B (zh)
WO (1) WO2015180678A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3150623B1 (en) * 2014-05-29 2019-04-03 Shanghai Techwell Biopharmaceutical Co., Ltd Solvate of cyclic peptide compound, preparation method for same, and uses thereof
CN106188228B (zh) * 2016-07-06 2019-03-22 厦门大学 一种基于四氟苯二甲腈构建稳定三元环肽的方法
CN108752430B (zh) * 2018-05-31 2022-02-18 杭州中美华东制药有限公司 米卡芬净钠新晶型及其制备方法
CN109232707B (zh) * 2018-09-17 2021-02-05 河南豫辰药业股份有限公司 一种甘草酸二铵原料药溶剂残留的去除方法
US12060439B2 (en) 2018-10-25 2024-08-13 Napp Pharmaceutical Group Limited Polymorph of echinocandin antifungal agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018615A1 (fr) * 2001-08-31 2003-03-06 Fujisawa Pharmaceutical Co., Ltd. Nouveau cristal de compose lipopeptidique cyclique

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102336818B (zh) * 2010-07-20 2014-04-02 上海天伟生物制药有限公司 一种肽类物质的晶体及其制备方法和用途
WO2012041801A1 (en) * 2010-09-28 2012-04-05 Dsm Sinochem Pharmaceuticals Netherlands B.V. Method for isolating a cyclohexapeptide
CA2832145C (en) * 2011-04-20 2020-10-20 Xellia Pharmaceuticals Aps Method for purification of micafungin
CN102952179B (zh) * 2011-08-24 2015-11-25 华北制药集团新药研究开发有限责任公司 一种高纯度米卡芬净前体化合物的制备方法
CN102659930B (zh) * 2012-03-30 2014-04-23 上海天伟生物制药有限公司 一种高纯度环肽类物质的晶体及其制备方法和用途
CN102627688B (zh) * 2012-03-30 2014-12-31 上海天伟生物制药有限公司 一种高纯度环肽化合物及其制备方法和用途
CN102627689B (zh) * 2012-03-30 2014-08-06 上海天伟生物制药有限公司 一种环肽类化合物的水合物及其制备方法和用途
EP3150623B1 (en) * 2014-05-29 2019-04-03 Shanghai Techwell Biopharmaceutical Co., Ltd Solvate of cyclic peptide compound, preparation method for same, and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018615A1 (fr) * 2001-08-31 2003-03-06 Fujisawa Pharmaceutical Co., Ltd. Nouveau cristal de compose lipopeptidique cyclique

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MICHIO, Y. ET AL.: "Study of Industrial Manufacturing Methods for Micafungin (FK463", THE SOCIETY FOR BIOTECHNOLOGY, vol. 83, no. 3, 31 December 2005 (2005-12-31), pages 123 - 131, XP008184481 *
See also references of EP3150624A4 *

Also Published As

Publication number Publication date
CN108276479B (zh) 2021-08-24
CN104877012A (zh) 2015-09-02
CN108276478A (zh) 2018-07-13
CN104877012B (zh) 2019-03-01
CN108276479A (zh) 2018-07-13
JP2016538329A (ja) 2016-12-08
CN108276478B (zh) 2021-09-28
US10138274B2 (en) 2018-11-27
EP3150624A4 (en) 2017-12-20
US20170198013A1 (en) 2017-07-13
JP6491217B2 (ja) 2019-03-27
EP3150624A1 (en) 2017-04-05

Similar Documents

Publication Publication Date Title
WO2015180678A1 (zh) 环肽类化合物的晶体及其制备方法和用途
WO2015180682A1 (zh) 一种环肽类化合物的溶剂合物及其制备方法和用途
TWI472515B (zh) 苯達莫斯汀鹽酸鹽（ｂｅｎｄａｍｕｓｔｉｎｅ ｈｙｄｒｏｃｈｌｏｒｉｄｅ）之新穎固體型式
CA2868988A1 (en) High purity cyclopeptide compound as well as preparation method and use thereof
WO2017193914A1 (zh) 克立硼罗游离形式的晶型及其制备方法和用途
JP6250629B2 (ja) 高純度のシクロペプチド系物質の結晶およびその製造方法と使用
GB2504042A (en) High purity of caspofungin or salts thereof, and preparation method therefor, and use thereof
KR101596554B1 (ko) 펩타이드계 물질의 결정체 및 그의 제조방법과 용도
CA2869014A1 (en) Hydrate of cyclopeptide compound as well as preparation method and use thereof
WO2018103027A1 (zh) 替吡法尼的晶型及其制备方法及药物组合物
WO2015180680A1 (zh) 一种环肽类化合物的结晶粉末及其制备方法和用途
WO2015180681A1 (zh) 一种环肽类化合物的组合物及其制备方法和用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15800606

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2016546138

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 15314797

Country of ref document: US

REEP Request for entry into the european phase

Ref document number: 2015800606

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2015800606

Country of ref document: EP